Fair Value Please, page-30

FAIR VALUE indeed.

$2 even as a starting point for an indicative, non-binding proposal is like a slap in the face for the long-term investors who have been here and supported this company.

For everything we know of this sector and the M&A activity that has gone on before us, to only end up with a $2 initial non-binding offer is absurd.

The only way we can get a fair price from these megacorporations (whether it be Sumi, Fuji or a US pharma) is if we are united for a common goal, a common target.

My personal T/O target, which I have expressed on here a few times over the past few years, has always been $4.
But given how things have played out in this sector over the last couple of years, and more specifically how our company have shown our tech to be worthy of a World-Class label, $5+ is certainly a fair ask.

When your technology could potentially be the last piece in the puzzle to dominate the regenerative medicine industry, do not let it go for cheap.